Association of common missense changes in ELAC2 (HPC2) with prostate cancer in a Japanese case - Control series

Journal of Human Genetics

Volumn 47, Issue 12, 2002, Pages 641-648

  Fujiwara, Hiromichi ^a   Emi, Mitsuru ^a   Nagai, Hisaki ^a   Nishimura, Taiji ^a   Konishi, Noboru ^b   Kubota, Yoshinobu ^c   Ichikawa, Tomohiko ^d   Takahashi, Satoru ^e   Shuin, Taro ^f   Habuchi, Tomonori ^g   Ogawa, Osamu ^h   Inoue, Katsuki ⁱ   Skolnick, Mark H ^j   Swensen, Jeff ^j   Camp, Nicola J ^k   Tavtigian, Sean V ^j  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^f KOCHI MEDICAL SCHOOL   (Japan)

^g AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KYOTO UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF HAWAII   (United States)

^j Utah   (United States)

^k UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

ELAC2; Genetics; HPC2; Modest risk variant; Prostate cancer

Indexed keywords

ALANINE; LEUCINE; SERINE; THREONINE;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER STAGING; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; ELAC2 GENE; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HPC2 GENE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; ONCOGENE; ONSET AGE; PROSTATE CANCER;

CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; JAPAN; MALE; MUTATION, MISSENSE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; VARIATION (GENETICS);

EID: 12244267055     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100380200099     Document Type: Article

References (18)

1. Armitage P (1955) Tests for linear trends in proportions and frequencies. Biometrics 11:375-386
2. Cochran WG (1954) Some methods of strengthening the common chi-squared tests. Biometrics 10:417-451
3. Cook LS, Goldoft M, Schwartz SM, Weiss NS (1999) Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol 161:152-155
4. Kolonel LN (1996) Racial and geographic variations in prostate cancer and the effect of migration. In: Fortner JG, Sharp PA (eds) Accomplishments in cancer research Lippincott-Raven, Philadelphia, pp 221-228
5. Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi CY, Yu MC, Henderson BE, Reichardt JK (1997) A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res 57:1020-1022
6. Muir C, Waterhouse J, Mack T, Powell J, Whelan S (1987) Cancer Incidence in five continents, Vol. 5. International Agency for Research on Cancer, Lyon, France
7. Parkin DM, Muir C, Whelan S (1992) Cancer incidence in five continents, Vol. 6. International Agency for Research on Cancer, Lyon, France
8. Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg S, Martin AM, Nathanson KL, Wein AJ, Malkowicz SB (2000) Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 67:1014-1019
9. Rokman A, Ikonen T, Mononen N, Autio V, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Schleutker J (2001) ELAC2/HPC2 involvment in hereditary and sporadic prostate cancer. Cancer Res 61:6038-6041
10. Shibata A, Whittemore AS, Imai K, Kolonel LN, Wu AH, John EM, Stamey TA, Paffenbarger RS (1997) Serum levels of prostate-specific antigen among Japanese-American and native Japanese men. J Natl Cancer Inst 89:1716-1720
11. Suarez BK, Gerhard DS, Lin J, Haberer B, Nguyen L, Kesterson NK, Catalona WJ (2001) Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Cancer Res 61:4982-4984
12. Tavtigian SV, Simard J, Labrie J, Skolnick MH, Neuhausen SL, Rommens J, Cannon-Albright LA (2000) A strong candidate prostate cancer predisposition gene at chromosome 17p. Am J Hum Genet suppl 67:11
13. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith, R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright LA (2001) A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 27:172-180
14. Vesprini D, Nam RK, Trachtenberg J, Jewett MA, Tavtigian SV, Emami M, Ho M, Toi A, Narod SA (2001) HPC2 variants and screen-detected prostate cancer. Am J Hum Genet 68:912-917
15. Walker AH, Jaffe JM, Gunasegaram S, Cummings SA, Huang CS, Chern HD, Olopade OI, Weber BL, Rebbeck TR (1998) Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191 (Online). Hum Mutat 12:289
16. Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN (2001) Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res 61:6494-6499
17. Xie X, Ott J (1993) Testing linkage disequilibrium between a disease gene and marker loci. Am J Hum Genet suppl 53:1107
18. Xu J, Zheng SL, Carpten JD, Nupponen NN, Robbins CM, Mestre J, Moses TY, Faith DA, Kelly BD, Isaacs SD, Wiley KE, Ewing CM, Bujnovszky P, Chang B, Bailey-Wilson J, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB (2001) Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet 68:901-911